<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03446144</url>
  </required_header>
  <id_info>
    <org_study_id>696844-CS3</org_study_id>
    <nct_id>NCT03446144</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)</brief_title>
  <official_title>A Phase 2, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of ISIS 696844, an Antisense Inhibitor of Complement Factor B, in Patients With Geographic Atrophy Secondary (GA) to Age-Related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the Safety and Efficacy of IONIS-FB-Lrx for up to 120
      patients with Geographic Atrophy secondary to Age Related Macular Degeneration
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess changes in complement factor B over a 69-week treatment period in a
      patient population 55 and older with well-demarcated Geographic Atrophy secondary to Age
      Related Macular Degeneration
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double Masked</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of IONIS-FB-Lrx</measure>
    <time_frame>Up to 74 weeks</time_frame>
    <description>The Efficacy of IONIS-FB-Lrx will be measured by the percent change in plasma complement factor B level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events that are related to treatment with IONIS-FB-Lrx</measure>
    <time_frame>Up to 86 weeks</time_frame>
    <description>The safety and tolerability of IONIS-FB-Lrx will be assessed by determining the incidence and severity of adverse events that are related to treatment with IONIS-FB-Lrx</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in each treatment group achieving a &gt;50% reduction of plasma complement factor B</measure>
    <time_frame>Up to 74 weeks</time_frame>
    <description>Proportion of patients in each treatment group achieving a &gt;50% reduction of plasma complement factor B from Baseline to Post-Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of IONIS-FB-Lrx on the rate of change of the area of GA secondary to AMD</measure>
    <time_frame>Up to 74 weeks</time_frame>
    <description>Effect of IONIS-FB-Lrx on the rate of change of the area of GA secondary to AMD as measured by Fundus Autofluorescence from Baseline to Post-Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of factor B reduction on other components of the complement pathways in AMD patients</measure>
    <time_frame>Up to 74 weeks</time_frame>
    <description>Effect of factor B reduction on other components of the complement pathways such as AH50, CH50 and Bb in AMD patients from Baseline to Post-Treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Geographic Atrophy</condition>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>IONIS-FB-Lrx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (sterile saline 0.9%)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS-FB-Lrx</intervention_name>
    <description>Single Dose of IONIS-FB-Lrx administered once weekly for weeks 1-3, and every other week or less frequently until week 70</description>
    <arm_group_label>IONIS-FB-Lrx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (sterline saline 0.9%)</intervention_name>
    <description>Calculated volume to match active comparator. Administered subcutaneously weekly for weeks 1-3, and every other week or less frequently until week 70</description>
    <arm_group_label>Placebo (sterile saline 0.9%)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Must have given written informed consent and be able to comply with study requirements

          2. Females must be non-pregnant and non-lactating, and either surgically sterile or
             post-menopausal. Males must be surgically sterile or, if engaged in sexual relations
             with a female of child bearing potential, the subject must be using an acceptable
             contraceptive method from the time of signing the informed consent form until at least
             a period of 13 weeks after the last dose of Study Drug (ISIS 696844 or placebo)

          3. Well-demarcated Geographic Atrophy due to Age Related Macular Degeneration

        Key Exclusion Criteria:

          1. Clinically-significant abnormalities in medical history

          2. Diagnosis of primary or secondary immunodeficiencies of B lymphocyte function,
             splenectomy, glomerulonephritis or history of recurrent meningococcal disease

          3. Diabetes mellitus or thyroid disease unless well controlled for a period of at least 3
             months

          4. Clinically-significant abnormalities in screening laboratory values

          5. Unwillingness to be administered, or history of a serious reaction to protocol
             required vaccines

          6. Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C
             or chronic hepatitis B

          7. History or presence of a disease other than AMD in study eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael McCaleb, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ionis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ionis Pharmaceuticals</last_name>
    <phone>800-679-4747</phone>
    <email>patients@ionisph.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>IONIS Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014-2709</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigational Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigative Site</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigative Site</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigational Site</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigational Site</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigative Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigational Site</name>
      <address>
        <city>Leawood</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigative Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107-5109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigative Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigational Site</name>
      <address>
        <city>Ladson</city>
        <state>South Carolina</state>
        <zip>29456</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigative Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701-7374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigative Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012-2505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231-5078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2727</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigative Site</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503-1518</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240-1502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IONIS Investigative Site</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384-8018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alan Luckie, Eye Clinic Albury Wodonga</name>
      <address>
        <city>Albury</city>
        <state>New South Wales</state>
        <zip>2640</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alex Breen</last_name>
      <phone>02 7022 4824</phone>
      <email>aecresearch@alburyeye.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IONIS Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jennifer Arnold, Marsden Eye Specialists</name>
      <address>
        <city>Paramatta</city>
        <state>New South Wales</state>
        <zip>2150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Arnold, Dr.</last_name>
      <phone>61 2 9635 7077</phone>
      <email>jennifer.arnold@marsdeneye.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>James Wong, Strathfield Retina Clinic</name>
      <address>
        <city>Strathfield</city>
        <state>New South Wales</state>
        <zip>2135</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Wong, Dr.</last_name>
      <phone>+61 2 9746 3378</phone>
      <email>info@strathfieldretina.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Andrew Chang, Sydney Retina Clinic Day Surgery</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Hong</last_name>
      <phone>02 9221 3755</phone>
    </contact>
    <contact_backup>
      <last_name>Kimberly Spooner</last_name>
      <phone>02 9221 3755</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Samantha Fraser-Bell, Sydney Eye Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Save Sight Institute</last_name>
      <phone>+61 2 9382 7286</phone>
    </contact>
    <contact_backup>
      <phone>+61 447222541</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Henry Newland, Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mel Willoughby</last_name>
      <phone>+61 8 7074 2257</phone>
      <email>Melanie.Willoughby@sa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Robyn Guymer, The Royal Victorian Eye and Ear Hospital</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sutha Sanmugasundram</last_name>
      <email>sans@unimelb.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Robin Guymer, Dr.</last_name>
      <email>Robyn.Guymer@eyeandear.org.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Wilson Heriot, Retinology Institute</name>
      <address>
        <city>Glen Iris</city>
        <state>Victoria</state>
        <zip>3146</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Lui</last_name>
      <phone>0410 142 677</phone>
      <email>sql@zave.com.au</email>
    </contact>
    <contact_backup>
      <last_name>Christine Farrugia</last_name>
      <phone>0411 045 897</phone>
      <email>caf@zave.com.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Heather Mack, Eye Surgery Associates</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Lui</last_name>
      <phone>0410 142 677</phone>
      <email>sql@zave.com.au</email>
    </contact>
    <contact_backup>
      <last_name>Christine Farrugia</last_name>
      <phone>0411 045 897</phone>
      <email>caf@zave.com.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Symons, Eye Surgery Associates</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Dang</last_name>
      <phone>03 9342 8449</phone>
      <email>Elizabeth.Dang@mh.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fred Chen, Lions Eye Institute</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fred Chen, Dr.</last_name>
      <phone>61 8 6382 0582</phone>
      <email>fredchen@lei.org.au</email>
    </contact>
    <contact_backup>
      <email>rachelmatthews@lei.org.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Philip Polkinghorne</name>
      <address>
        <city>Auckland</city>
        <zip>1050</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>research@aucklandeye.co.nz</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2018</study_first_submitted>
  <study_first_submitted_qc>February 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Geographic Atrophy</keyword>
  <keyword>Age Related Macular Degeneration</keyword>
  <keyword>IONIS-FB-Lrx</keyword>
  <keyword>Complement Factor B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement System Proteins</mesh_term>
    <mesh_term>Complement Factor B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

